The SPRINT study, which explored the effect of targeting blood pressure treatment to a goal of < 120 mmHg, ended early because of significantly lower rates of fatal and nonfatal cardiovascular events and death from any cause. However, the incidence of acute kidney damage hypotension, syncope, and electrolyte abnormalities were higher in the treatment group. A recent meta-analysis also supports the benefit of targeting lower blood pressure levels.SOURCES:
The SPRINT research group: A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 2015;373:2103-2116.SOURCES:
Xie X, et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: Updated systematic review and meta-analysis. Lancet 2015 Nov. pii: S0140-6736(15)00805-3. doi: 10.1016/S0140-6736(15)00805-3. [Epub ahead of print].